TD Cowen Starts Celldex Therapeutics (CLDX) at Outperform; 'barzolvolimab has blockbuster potential'
Tweet Send to a Friend
(Updated - December 20, 2023 6:16 AM EST)
TD Cowen analyst Yaron Werber initiates coverage on Celldex Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
TD Cowen analyst Yaron Werber initiates coverage on Celldex Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
